TNF and rheumatoid arthritis: For instance, the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance study compared comparing tofacitinib with tumor necrosis factor (TNF) inhibitors and found an increased risk of cardiovascular events and malignancies with tofacitinib.